Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Parkinsons Dis ; 7(2): 325-330, 2017.
Article in English | MEDLINE | ID: mdl-28222537

ABSTRACT

BACKGROUND: Nonmotor symptoms (NMS) are known to fluctuate together with motor oscillations in advanced PD, but their timing and kinetics remains enigmatic. OBJECTIVE: To evaluate timing and kinetics of NMS fluctuations. METHODS: Analysis of diary data from 17 fluctuating PD patients. Diaries were completed by rating NMS as absent (defined herein as NMS On state) or present (NMS Off state) and motor function for every hour for 5 consecutive days. Timing and kinetics were analyzed by synchronizing motor Off periods and subsequent cross-classification of NMS Off periods for each motor Off hour into 2×2 contingency tables. RESULTS: We found clear temporal connections of NMS Off periods with motor Off periods only for anxiety/depression, concentration/attention deficiency and bladder urgency. Psychiatric NMS Off periods had a longer duration (median: 3-4 hours) compared to motor Off periods (2 hours; P < 0.05, Mann-Whitney U-test). CONCLUSIONS: Our data on timing and kinetics of NMS fluctuations show close temporal connection with motor Off periods only for mood and cognitive symptoms. Variances in both timing and/or kinetics of NMS fluctuations might explain both the weak/absent correlations of NMS and motor symptom severity in fluctuating patients and the rather low rates of simultaneous switches between On and Off states for NMS and motor function.


Subject(s)
Parkinson Disease/physiopathology , Parkinson Disease/psychology , Aged , Aged, 80 and over , Anxiety/complications , Attention , Depression/complications , Fatigue/complications , Female , Humans , Male , Middle Aged , Parkinson Disease/complications , Pilot Projects , Time Factors , Urinary Bladder, Overactive/complications
2.
J Neurochem ; 140(1): 126-139, 2017 01.
Article in English | MEDLINE | ID: mdl-27861893

ABSTRACT

Locally synthesized estradiol plays an important role in synaptic plasticity in the hippocampus. We have previously shown that in hippocampal neurons, activity of the enzyme aromatase, which converts testosterone into estradiol, is reduced via Ca2+ -dependent phosphorylation. Synaptopodin is a highly estrogen responsive protein, and it has been shown that it is an important regulator of synaptic plasticity, mediated by its close association with internal calcium stores. In this study, we show that the expression of synaptopodin is stronger in the hippocampus of female animals than in that of male animals. Phosphorylation of aromatase, using letrozole, however, down-regulates synaptopodin immunohistochemistry in the hippocampus of both male and females. Similarly, in aromatase knock-out mice synaptopodin expression in the hippocampus is reduced sex independently. Using primary-dissociated hippocampal neurons, we found that evoked release of Ca2+ from internal stores down-regulates aromatase activity, which is paralleled by reduced expression of synaptopodin. Opposite effects were achieved after inhibition of the release. Calcium-dependent regulation of synaptopodin expression was abolished when the control of aromatase activity by the Ca2+ transients was disrupted. Our data suggest that the regulation of aromatase activity by Ca2+ transients in neurons contributes to synaptic plasticity in the hippocampus of male and female animals as an on-site regulatory mechanism.


Subject(s)
Aromatase Inhibitors/pharmacology , Aromatase/metabolism , Microfilament Proteins/physiology , Animals , Calcium Signaling/drug effects , Calcium Signaling/physiology , Cells, Cultured , Enzyme Activation/drug effects , Enzyme Activation/physiology , Female , Hippocampus/drug effects , Hippocampus/metabolism , Letrozole , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitriles/pharmacology , Rats , Rats, Wistar , Triazoles/pharmacology
3.
PLoS One ; 11(8): e0161559, 2016.
Article in English | MEDLINE | ID: mdl-27556806

ABSTRACT

INTRODUCTION: Effective management and development of new treatment strategies for response fluctuations in advanced Parkinson's disease (PD) largely depends on clinical rating instruments such as the PD home diary. The Parkinson's kinetigraph (PKG) measures movement accelerations and analyzes the spectral power of the low frequencies of the accelerometer data. New algorithms convert each hour of continuous PKG data into one of the three motor categories used in the PD home diary, namely motor Off state and On state with and without dyskinesia. OBJECTIVE: To compare quantitative motor state assessment in fluctuating PD patients using the PKG with motor state ratings from PD home diaries. METHODS: Observational cohort study on 24 in-patients with documented motor fluctuations who completed diaries by rating motor Off, On without dyskinesia, On with dyskinesia, and asleep for every hour for 5 consecutive days. Simultaneously collected PKG data (recorded between 6 am and 10 pm) were analyzed and calibrated to the patient's individual thresholds for Off and dyskinetic state by novel algorithms classifying the continuous accelerometer data into these motor states for every hour between 6 am and 10 pm. RESULTS: From a total of 2,040 hours, 1,752 hours (87.4%) were available for analyses from calibrated PKG data (7.5% sleeping time and 5.1% unclassified motor state time were excluded from analyses). Distributions of total motor state hours per day measured by PKG showed moderate-to-strong correlation to those assessed by diaries for the different motor states (Pearson's correlations coefficients: 0.404-0.658), but inter-rating method agreements on the single-hour-level were only low-to-moderate (Cohen's κ: 0.215-0.324). CONCLUSION: The PKG has been shown to capture motor fluctuations in patients with advanced PD. The limited correlation of hour-to-hour diary and PKG recordings should be addressed in further studies.


Subject(s)
Dyskinesias/physiopathology , Health Records, Personal , Parkinson Disease/diagnosis , Parkinson Disease/physiopathology , Aged , Aged, 80 and over , Cohort Studies , Dyskinesias/diagnosis , Female , Humans , Male , Middle Aged , Severity of Illness Index
4.
J Parkinsons Dis ; 6(3): 597-607, 2016 05 31.
Article in English | MEDLINE | ID: mdl-27258695

ABSTRACT

BACKGROUND: Since previous studies aimed to study nonmotor symptom (NMS) fluctuations in direct conjunction with motor oscillations, there are no data available on the temporal context of NMS fluctuations and motor oscillations in advanced Parkinson's disease (PD). OBJECTIVE: To evaluate circadian patterns and temporal connections of NMS and motor fluctuations in PD. METHODS: 15 controls, 17 non-fluctuating and 15 fluctuating PD patients completed two diaries by rating 4 key psychiatric (anxiety, depressive mood, inner restlessness, concentration/attention deficits), fatigue and 4 autonomic NMS (excessive sweating, sialorrhea, bladder urgency, dizziness) absent or present and motor function (Off, On with/without dyskinesia, and asleep) for every hour for 5 consecutive days. RESULTS: NMS Off state hours (hours with NMS rated as present) were less frequent compared to motor Off state hours and NMS On-Off-switches were less prevalent compared to those of the motor state. Off time and number of On-Off-switches of psychiatric NMS were moderately correlated with motor Off time and number of motor On-Off switches on the individual patient level. Changes in NMS state occurred largely independent of changes in motor states with concordance rates of only 26-43% of all NMS changes for psychiatric and 7-17% for autonomic NMS. In controls and non-fluctuating PD patients, there were no NMS state switches in concordance to motor state switches. CONCLUSION: We provide first data on the temporal context of NMS fluctuations showing similar frequencies of psychiatric NMS Off, fatigue Off and motor Off times as well as their On-Off-fluctuations, but low concordance rates of NMS with motor On-Off-state switches. We found no evidence for NMS fluctuations in non-fluctuating PD patients. Our data implicate similar fluctuation patterns of mood NMS and motor function without close timing and/or different kinetics.


Subject(s)
Circadian Rhythm/physiology , Parkinson Disease/physiopathology , Severity of Illness Index , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Time Factors
5.
J Neural Transm (Vienna) ; 123(1): 57-64, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26253901

ABSTRACT

Effective management and development of new treatment strategies of motor symptoms in Parkinson's disease (PD) largely depend on clinical rating instruments like the Unified PD rating scale (UPDRS) and the modified abnormal involuntary movement scale (mAIMS). Regarding inter-rater variability and continuous monitoring, clinical rating scales have various limitations. Patient-administered questionnaires such as the PD home diary to assess motor stages and fluctuations in late-stage PD are frequently used in clinical routine and as clinical trial endpoints, but diary/questionnaire are tiring, and recall bias impacts on data quality, particularly in patients with cognitive dysfunction or depression. Consequently, there is a strong need for continuous and objective monitoring of motor symptoms in PD for improving therapeutic regimen and for usage in clinical trials. Recent advances in battery technology, movement sensors such as gyroscopes, accelerometers and information technology boosted the field of objective measurement of movement in everyday life and medicine using wearable sensors allowing continuous (long-term) monitoring. This systematic review summarizes the current wearable sensor-based devices to objectively assess the various motor symptoms of PD.


Subject(s)
Monitoring, Ambulatory/instrumentation , Monitoring, Ambulatory/methods , Movement/physiology , Parkinson Disease/diagnosis , Parkinson Disease/physiopathology , Humans , PubMed/statistics & numerical data , Severity of Illness Index , Surveys and Questionnaires
6.
Neurol Clin ; 33(1): 19-37, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25432721

ABSTRACT

The initiation of therapy in Parkinson disease (PD), altering the medication, adding new substances, and switching to alternative therapies throughout the disease is always a matter of debate. In the past, experts in PD have propagated different medication strategies. Even though there is no new medical treatment on the horizon, much has changed in consideration of the known treatments in the early and advanced therapy for PD. Therapeutic regimens have to be adapted and adjusted on a regular basis to accomplish the best medical care for the predominant symptom of the individual patient with PD.


Subject(s)
Antiparkinson Agents/therapeutic use , Parkinson Disease/diagnosis , Parkinson Disease/therapy , Humans
7.
Stem Cells Transl Med ; 4(1): 31-43, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25479965

ABSTRACT

Parkinson's disease (PD) is considered the second most frequent and one of the most severe neurodegenerative diseases, with dysfunctions of the motor system and with nonmotor symptoms such as depression and dementia. Compensation for the progressive loss of dopaminergic (DA) neurons during PD using current pharmacological treatment strategies is limited and remains challenging. Pluripotent stem cell-based regenerative medicine may offer a promising therapeutic alternative, although the medical application of human embryonic tissue and pluripotent stem cells is still a matter of ethical and practical debate. Addressing these challenges, the present study investigated the potential of adult human neural crest-derived stem cells derived from the inferior turbinate (ITSCs) transplanted into a parkinsonian rat model. Emphasizing their capability to give rise to nervous tissue, ITSCs isolated from the adult human nose efficiently differentiated into functional mature neurons in vitro. Additional successful dopaminergic differentiation of ITSCs was subsequently followed by their transplantation into a unilaterally lesioned 6-hydroxydopamine rat PD model. Transplantation of predifferentiated or undifferentiated ITSCs led to robust restoration of rotational behavior, accompanied by significant recovery of DA neurons within the substantia nigra. ITSCs were further shown to migrate extensively in loose streams primarily toward the posterior direction as far as to the midbrain region, at which point they were able to differentiate into DA neurons within the locus ceruleus. We demonstrate, for the first time, that adult human ITSCs are capable of functionally recovering a PD rat model.


Subject(s)
Neural Crest/transplantation , Neural Stem Cells/transplantation , Parkinsonian Disorders/surgery , Recovery of Function , Adult Stem Cells/cytology , Adult Stem Cells/transplantation , Animals , Cell Differentiation , Female , Heterografts , Humans , Immunohistochemistry , Neural Crest/cytology , Neural Stem Cells/cytology , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Stem Cell Transplantation/methods
8.
Cell Rep ; 8(6): 1697-1703, 2014 Sep 25.
Article in English | MEDLINE | ID: mdl-25220454

ABSTRACT

The differentiation capability of induced pluripotent stem cells (iPSCs) toward certain cell types for disease modeling and drug screening assays might be influenced by their somatic cell of origin. Here, we have compared the neural induction of human iPSCs generated from fetal neural stem cells (fNSCs), dermal fibroblasts, or cord blood CD34(+) hematopoietic progenitor cells. Neural progenitor cells (NPCs) and neurons could be generated at similar efficiencies from all iPSCs. Transcriptomics analysis of the whole genome and of neural genes revealed a separation of neuroectoderm-derived iPSC-NPCs from mesoderm-derived iPSC-NPCs. Furthermore, we found genes that were similarly expressed in fNSCs and neuroectoderm, but not in mesoderm-derived iPSC-NPCs. Notably, these neural signatures were retained after transplantation into the cortex of mice and paralleled with increased survival of neuroectoderm-derived cells in vivo. These results indicate distinct origin-dependent neural cell identities in differentiated human iPSCs both in vitro and in vivo.


Subject(s)
Brain/metabolism , Induced Pluripotent Stem Cells/cytology , Neural Stem Cells/cytology , Animals , Antigens, CD34/metabolism , Cell Differentiation , Cells, Cultured , Fetal Blood/cytology , Fetal Blood/metabolism , Fetus/cytology , Fibroblasts/cytology , Gene Expression Profiling , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Hematopoietic Stem Cells/cytology , Humans , Induced Pluripotent Stem Cells/metabolism , Induced Pluripotent Stem Cells/transplantation , Mesoderm/cytology , Mice , Mice, Inbred NOD , Microscopy, Confocal , Neural Plate/cytology
9.
Psychoneuroendocrinology ; 34 Suppl 1: S123-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19781860

ABSTRACT

Estrogen-induced synaptic plasticity was frequently shown by an increase of spines at apical dendrites of CA1 pyramidal neurons after systemic application of estradiol to ovariectomized rats. Surprisingly, exogenous application of estradiol to hippocampal cultures had no effect on spines and on spine synapses, although quantitative immunohistochemistry revealed an upregulation of spinophilin and of synaptophysin, in these cultures. The role of synaptophysin as a presynaptic marker and of spinophilin as a postsynaptic marker, appears questionable from these discrepancies. In contrast, synaptopodin, a marker protein of "mature" mushroom-shaped spines, was downregulated after treatment of hippocampal cultures with estradiol. Synaptopodin is strongly associated to the spine apparatus, a spine-specific cell organelle, which is present in 80% of all mushroom-shaped spines. Consistently, we found a reduction in the number of spines, containing a spine apparatus in response to estradiol, suggesting that the presence of a spine apparatus in many but not all spines is very likely a result of their dynamic character. In summary, synaptic proteins appear to be regulated by estradiol, independent of its function on spine and spine synapse formation.


Subject(s)
Estradiol/pharmacology , Estradiol/physiology , Hippocampus/drug effects , Synapses/metabolism , Animals , Dendritic Spines/metabolism , Dendritic Spines/ultrastructure , Down-Regulation/drug effects , Hippocampus/metabolism , Mice , Microfilament Proteins/metabolism , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Receptors, Estrogen/drug effects , Receptors, Estrogen/metabolism , Synapses/ultrastructure , Synaptophysin/metabolism , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...